Lomexin Cream is formulated for skin infections and does not penetrate the nail plate effectively. For onychomycosis, oral antifungal agents or specialized nail lacquers are typically recommended.
Both contain imidazole antifungals, but fenticonazole nitrate has a broader spectrum against resistant dermatophytes and Candida species. Clinical choice depends on infection type, patient tolerance, and prescriber preference.
The medication is category B3 in the UK, indicating no well-controlled studies in humans. It should be used only if the potential benefit outweighs any potential risk, after professional assessment.
Discontinue use immediately and seek medical evaluation. A rash may indicate allergic contact dermatitis, which requires alternative therapy.
Covering the treated area with an airtight dressing can increase absorption and irritation. Use only non-occlusive dressings unless advised by a clinician.
Lomexin Cream is typically a pale, white to off-white cream with a mild fragrance designed to be non-irritating. Any significant change in appearance should prompt disposal.
Topical antifungals are not listed on standard doping panels. However, athletes should disclose all topical medications to their governing body if required.
After opening, the cream remains stable for 30 days if stored correctly. Check the package for the specific “use-by” date after opening.
The tube should be recycled where facilities exist, otherwise placed in household waste. Do not flush the cream down the toilet, as active ingredients can affect water treatment processes.
Safety and efficacy have not been established for children under 12 years. For infant fungal infections, a pediatric-specific formulation should be prescribed.
Lomexin Cream contains the active ingredient Fenticonazole Nitrate, a broad-spectrum antifungal agent. It is supplied in a 30 g tube and is classified as a topical antifungal for the treatment of superficial fungal skin infections. In the United Kingdom, Lomexin Cream is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Fenticonazole Nitrate belongs to the imidazole class of antifungals. It inhibits the synthesis of ergosterol, a key component of fungal cell membranes. By disrupting ergosterol production, the drug compromises membrane integrity, leading to increased cell permeability and ultimately fungal cell death. The medication is absorbed minimally through intact skin, allowing it to act locally at the site of infection while limiting systemic exposure.
Lomexin Cream is approved by the MHRA for the following indications:
These conditions involve superficial dermatophyte or yeast infections that respond well to topical imidazole therapy.
Topical fenticonazole nitrate has limited systemic absorption, so clinically significant drug-drug interactions are uncommon. However:
Note: Patients should inform their healthcare provider of all concurrent medications, herbal supplements, and over-the-counter products before starting Lomexin Cream.
If dosing specifics are unclear for an individual case, the prescribing clinician will tailor the regimen based on infection severity, site, and patient response.
This article provides educational information about Lomexin Cream and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
